
    
      The total study duration per participant was up to 46 weeks, consisting of a screening period
      of 3 to up to 8 weeks (up to 10 weeks for participants who experienced a clinically
      significant asthma exacerbation during the screening period), a randomized treatment period
      of up to 24 weeks, and a post-treatment period of 12 weeks.

      Participants who completed treatment were considered for eligibility into the long term
      extension study LTS12551 (NCT02134028).
    
  